Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2016 (2016), Article ID 1239861, 11 pages
http://dx.doi.org/10.1155/2016/1239861
Research Article

Modeling the Treatment of Glioblastoma Multiforme and Cancer Stem Cells with Ordinary Differential Equations

1Department of Mathematics, Winthrop University, Rock Hill, SC 29733, USA
2Department of Mathematics, Vassar College, Poughkeepsie, NY 12604, USA

Received 3 September 2015; Revised 12 November 2015; Accepted 22 December 2015

Academic Editor: Chung-Min Liao

Copyright © 2016 Kristen Abernathy and Jeremy Burke. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Louzoun, C. Xue, G. B. Lesinski, and A. Friedman, “A mathematical model for pancreatic cancer growth and treatments,” Journal of Theoretical Biology, vol. 351, pp. 74–82, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. Thomas and J. Massagué, “TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance,” Cancer Cell, vol. 8, no. 5, pp. 369–380, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Mason, A stochastic Markov chain model to describe cancer metastasis [Ph.D. thesis], University of Southern California, 2013.
  4. N. L. Komarova, “Spatial stochastic models of cancer: fitness, migration, invasion,” Mathematical Biosciences and Engineering, vol. 10, no. 3, pp. 761–775, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. B. T. Tan, C. Y. Park, L. E. Ailles, and I. L. Weissman, “The cancer stem cell hypothesis: a work in progress,” Laboratory Investigation, vol. 86, no. 12, pp. 1203–1207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Beretta, V. Capasso, and N. Morozova, “Mathematical modelling of cancer stem cells population behavior,” Mathematical Modelling of Natural Phenomena, vol. 7, no. 1, pp. 279–305, 2012. View at Publisher · View at Google Scholar · View at Zentralblatt MATH · View at Scopus
  7. G. Hochman and Z. Agur, “Deciphering fate decision in normal and cancer stem cells: mathematical models and their experimental verification,” in Mathematical Methods and Models in Biomedicine, Lecture Notes on Mathematical Modelling in the Life Sciences, pp. 203–232, Springer, New York, NY, USA, 2013. View at Publisher · View at Google Scholar
  8. V. Vainstein, O. U. Kirnasovsky, Y. Kogan, and Z. Agur, “Strategies for cancer stem cell elimination: insights from mathematical modeling,” Journal of Theoretical Biology, vol. 298, pp. 32–41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Youssefpour, Mathematical modeling of cancer stem cells and therapeutic intervention methods [Ph.D. thesis], University of California, Irvine, Calif, USA, 2013.
  10. N. Kronik, Y. Kogan, V. Vainstein, and Z. Agur, “Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics,” Cancer Immunology, Immunotherapy, vol. 57, no. 3, pp. 425–439, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. E. Prince, R. Sivanandan, A. Kaczorowski et al., “Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 3, pp. 973–978, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Ganguly and I. K. Puri, “Mathematical model for the cancer stem cell hypothesis,” Cell Proliferation, vol. 39, no. 1, pp. 3–14, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Kogan, U. Forys, and N. Kronik, “Analysis of the immunotherapy model for glioblastoma multiform brain tumour,” Tech. Rep. 178, Institute of Applied Mathematics and Mechanics UW, 2008. View at Google Scholar
  14. C. A. Kruse, L. Cepeda, B. Owens, S. D. Johnson, J. Stears, and K. O. Lillehei, “Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2,” Cancer Immunology Immunotherapy, vol. 45, no. 2, pp. 77–87, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. W. F. Hickey, “Basic principles of immunological surveillance of the normal central nervous system,” Glia, vol. 36, no. 2, pp. 118–124, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Kirschner and J. C. Panetta, “Modeling immunotherapy of the tumor—immune interaction,” Journal of Mathematical Biology, vol. 37, no. 3, pp. 235–252, 1998. View at Publisher · View at Google Scholar
  17. A. Suzumura, M. Sawada, H. Yamamoto, and T. Marunouchi, “Transforming growth factor-β suppresses activation and proliferation of microglia in vitro,” The Journal of Immunology, vol. 151, no. 4, pp. 2150–2158, 1993. View at Google Scholar · View at Scopus
  18. J. C. Robinson, Infinite-Dimensional Dynamical Systems, Cambridge University Press, New York, NY, USA, 2001. View at MathSciNet
  19. P. C. Burger, F. S. Vogel, S. B. Green, and T. A. Strike, “Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications,” Cancer, vol. 56, no. 5, pp. 1106–1111, 1985. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Turner, A. R. Stinchcombe, M. Kohandel, S. Singh, and S. Sivaloganathan, “Characterization of brain cancer stem cells: a mathematical approach,” Cell Proliferation, vol. 42, no. 4, pp. 529–540, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. J. C. Arciero, T. L. Jackson, and D. E. Kirschner, “A mathematical model of tumor-immune evasion and siRNA treatment,” Discrete and Continuous Dynamical Systems Series B, vol. 4, no. 1, pp. 39–58, 2004. View at Publisher · View at Google Scholar
  22. W. D. Wick, O. O. Yang, L. Corey, and S. G. Self, “How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?” Journal of Virology, vol. 79, no. 21, pp. 13579–13586, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Kageyama, T. J. Tsomides, Y. Sykulev, and H. N. Eisen, “Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses,” The Journal of Immunology, vol. 154, no. 2, pp. 567–576, 1995. View at Google Scholar · View at Scopus
  24. P. K. Peterson, C. C. Chao, S. Hu, K. Thielen, and E. G. Shaskan, “Glioblastoma, transforming growth factor-β, and Candida meningitis: a potential link,” The American Journal of Medicine, vol. 92, no. 3, pp. 262–264, 1992. View at Publisher · View at Google Scholar · View at Scopus
  25. G. P. Taylor, S. E. Hall, S. Navarrete et al., “Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy,” Journal of Virology, vol. 73, no. 12, pp. 10289–10295, 1999. View at Google Scholar · View at Scopus
  26. R. J. Coffey Jr., L. J. Kost, R. M. Lyons, H. L. Moses, and N. F. LaRusso, “Hepatic processing of transforming growth factor β in the rat: uptake, metabolism, and biliary excretion,” The Journal of Clinical Investigation, vol. 80, no. 3, pp. 750–757, 1987. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Yang, T. J. Kremen, A. J. Giovannone et al., “Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex—bound immunogenic peptides induced by interferon-α and interferon-γ treatment of human glioblastoma multiforme,” Journal of Neurosurgery, vol. 100, no. 2, pp. 310–319, 2004. View at Publisher · View at Google Scholar
  28. E. Milner, E. Barnea, I. Beer, and A. Admon, “The turnover kinetics of MHC peptides of human cancer cells,” Molecular & Cellular Proteomics, vol. 5, pp. 366–378, 2006. View at Google Scholar
  29. L. M. Phillips, P. J. Simon, and L. A. Lampson, “Site-specific immune regulation in the brain: differential modulation of major histocompatibility complex (MHC) proteins in brainstem vs. hippocampus,” Journal of Comparative Neurology, vol. 405, no. 3, pp. 322–333, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Bosshart and R. F. Jarrett, “Deficient major histocompatibility complex class II antigen presentation in a subset of Hodgkin's disease tumor cells,” Blood, vol. 92, no. 7, pp. 2252–2259, 1998. View at Google Scholar
  31. C. A. Lazarski, F. A. Chaves, S. A. Jenks et al., “The kinetic stability of MHC class II: peptide complexes is a key parameter that dictates immunodominance,” Immunity, vol. 23, no. 1, pp. 29–40, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. J. Kim, L. K. Nottingham, J. I. Sin et al., “CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines,” The Journal of Clinical Investigation, vol. 102, no. 6, pp. 1112–1124, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. P. K. Turner, J. A. Houghton, I. Petak et al., “Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer,” Cancer Chemotherapy and Pharmacology, vol. 53, no. 3, pp. 253–260, 2004. View at Publisher · View at Google Scholar · View at Scopus